93.94 0.08 (0.09%) | 03-28 16:00 | |||||||||||||
|
|
Short term | ||||
Mid term | ||||
Targets | 6-month : | 110.79 | 1-year : | 129.41 |
Resists | First : | 94.86 | Second : | 110.79 |
Pivot price | 92.69 | |||
Supports | First : | 87.56 | Second : | 83.05 |
MAs | MA(5) : | 93.43 | MA(20) : | 92.08 |
MA(100) : | 74.96 | MA(250) : | 71.94 | |
MACD | MACD : | 3 | Signal : | 3.5 |
%K %D | K(14,3) : | 69.7 | D(3) : | 68.5 |
RSI | RSI(14): 71.4 | |||
52-week | High : | 94.86 | Low : | 53.79 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ BRKR ] has closed below upper band by 16.3%. Bollinger Bands are 59.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 5 bars. This is a sign that the market may be about to initiate a new trend.
If tomorrow: | Open lower | Open higher |
High: | 94.64 - 95.09 | 95.09 - 95.5 |
Low: | 92.02 - 92.55 | 92.55 - 93.04 |
Close: | 93.07 - 93.94 | 93.94 - 94.73 |
Bruker Corporation develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States and internationally. The company operates through three segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. It offers life science tools, and single and multiple modality systems; life science mass spectrometry; MALDI Biotyper rapid pathogen identification platform and related test kits, DNA test strips, and fluorescence-based polymerase chain reaction technology; genotype and fluorotype molecular diagnostics kits; research, analytical, and process analysis instruments and solutions; SARS-CoV 2 testing for the diagnosis of COVID-19 infection; and Fluorotyper-SARS-CoV 2 plus kits. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; products and services to support the multi-omics needs of researchers in translational research, drug, and biomarker discovery; superconducting materials, such as metallic low temperature superconductors; devices and complex tools based on metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. Bruker Corporation has a collaboration with Newomics Inc. on a LC-MS platform for drug discovery. The company was incorporated in 1991 and is headquartered in Billerica, Massachusetts.
Thu, 28 Mar 2024
Bruker Co. (NASDAQ:BRKR) Given Average Rating of "Hold" by Analysts - MarketBeat
Thu, 28 Mar 2024
SG Americas Securities LLC Purchases 6647 Shares of Bruker Co. (NASDAQ:BRKR) - Defense World
Thu, 28 Mar 2024
Bruker Co. (NASDAQ:BRKR) Receives Consensus Recommendation of “Hold” from Brokerages - Defense World
Wed, 27 Mar 2024
Bruker (BRKR) Reports Q2 Earnings: What Key Metrics Have to Say - Yahoo Movies Canada
Fri, 22 Mar 2024
Bruker Corporation (BRKR) Hits 52-Week High: What's Driving It? - Yahoo Finance
Thu, 07 Mar 2024
Bruker Announces Closing of Chemspeed Technologies AG Acquisition - Yahoo Finance
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Outperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Medical - Devices
|
|
Shares Out | 138 (M) |
Shares Float | 89 (M) |
Held by Insiders | 34.6 (%) |
Held by Institutions | 80.9 (%) |
Shares Short | 4,380 (K) |
Shares Short P.Month | 3,720 (K) |
EPS | 2.9 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 9.48 |
Profit Margin | 14.4 % |
Operating Margin | 16 % |
Return on Assets (ttm) | 7.6 % |
Return on Equity (ttm) | 33.6 % |
Qtrly Rev. Growth | 20.6 % |
Gross Profit (p.s.) | 0 |
Sales Per Share | 21.5 |
EBITDA (p.s.) | 4.35 |
Qtrly Earnings Growth | 112.6 % |
Operating Cash Flow | 350 (M) |
Levered Free Cash Flow | 292 (M) |
PE Ratio | 32.39 |
PEG Ratio | 2.4 |
Price to Book value | 9.89 |
Price to Sales | 4.36 |
Price to Cash Flow | 36.94 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |